Nanexa

Nanexa FCF/Debt

The Free Cash Flow to Debt Ratio of Nanexa (NANEXA.ST) as of Nov 5, 2026 is -1,192.99 %. In the previous year, Free Cash Flow to Debt Ratio was -1,472.33 % — a change of -18.97% (higher).

FCF/Debt

-1,192.99 %

YoY

-18.97%

Last updated:

Free Cash Flow to Debt Ratio of Nanexa is 2025 -1,192.99 % . Free Cash Flow to Debt Ratio of Nanexa was 2024 -1,472.33 % . It decreases by -18.97% higher compared to the previous year.

The Nanexa FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-229.01 SEK
Jan 1, 2019
-389.37 SEK
Jan 1, 2020
-968.27 SEK
Jan 1, 2021
-1,328.73 SEK
Jan 1, 2022
-690.26 SEK
Jan 1, 2023
-1,907.39 SEK
Jan 1, 2024
-1,472.33 SEK
Jan 1, 2025
-1,192.99 SEK
The Nanexa FCF/Debt history
YEARFCF/DebtYoY
-1,192.99 %-18.97%
-1,472.33 %-22.81%
-1,907.39 %+176.33%
-690.26 %-48.05%
-1,328.73 %+37.23%
-968.27 %+148.68%
-389.37 %+70.03%
-229.01 %-30.42%
-329.13 %-28.88%
-462.81 %-67.72%
-1,433.64 %-989.58%
161.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanexa Stock analysis

What does Nanexa do? Nanexa AB develops and distributes medical nanotechnology products including PharmaShell, a drug delivery system for targeted dosing, and antifungal coating that protects medical products from fungal growth. The company also offers low-friction coating for peripheral venous catheters. Its products are sold to healthcare providers and medical device manufacturers seeking advanced solutions for drug delivery and infection prevention. Nanexa AB's revenue comes from the sale of its nanotechnology-based products to healthcare institutions and medical device companies. The firm focuses on life science R&D, targeting applications in pharmaceuticals and medical device manufacturing. Its product portfolio serves the healthcare sector by enhancing drug efficacy and protecting medical equipment from microbial contamination. The company's business model relies on selling specialized coatings and delivery systems to medical professionals and manufacturers. PharmaShell enables precise drug targeting, while antifungal and low-friction coatings address specific clinical needs in medical device usage. These products are designed to improve patient outcomes and reduce complications in medical treatments. Nanexa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanexa stock

Free Cash Flow to Debt Ratio of Nanexa is -1,192.99 % in 2025.

Free Cash Flow to Debt Ratio of Nanexa changed from -1,472.33 % to -1,192.99 %, representing a -18.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Nanexa since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Nanexa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Nanexa

All Key Metrics — Nanexa